Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TK2 | O00142 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9021896 | 0.79 | TK1 (0.56) | TK1TK2 | |
| SCHEMBL17791229 | 0.79 | CYP1A2 (0.49) | CYP3A4CYP1A2CYP2D6TK1KMT2A | |
| SCHEMBL4564516 | 0.79 | GRIA1 (0.49) | CYP1A2KMT2AALDH1A1 | |
| SCHEMBL4273433 | 0.78 | DPYD (0.31) | — | |
| SCHEMBL12410891 | 0.77 | TK1 (0.41) | CYP3A4CYP1A2CYP2D6TK1MAPT | |
| SCHEMBL2248519 | 0.75 | KMT2A (0.52) | CYP3A4CYP1A2CYP2C9KMT2AKDM4E | |
| SCHEMBL1558433 | 0.73 | TK2 (0.42) | CYP3A4CYP1A2CYP2D6TK1KMT2A | |
| SCHEMBL1558432 | 0.73 | TK2 (0.42) | CYP3A4CYP1A2CYP2D6TK1KMT2A | |
| SCHEMBL17243367 | 0.73 | KMT2A (0.36) | CYP3A4CYP1A2CYP2D6TK1MAPT | |
| SCHEMBL12410794 | 0.73 | TK1 (0.42) | CYP3A4CYP1A2CYP2D6TK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250320496-A1 | MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-10-16 | — | — | US | claimed |
| EP-4627084-A1 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | Camp4 Therapeutics Corporation (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250290072-A1 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-09-18 | — | — | US | claimed |
| US-20250250575-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-08-07 | — | — | US | claimed |
| US-20250243488-A1 | METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-07-31 | — | — | US | claimed |
| WO-2024119145-A9 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-3887514-A2 | THERAPEUTIC GENE EDITING FOR ELANE-ASSOCIATED DISEASE | The Children's Medical Center Corporation (US) | 2021-10-06 | — | — | EP | claimed |
| WO-2021067233-A1 | BCL11A GUIDE AND BASE EDITOR DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-04-08 | — | — | WO | claimed |
| EP-3794130-A1 | METHODS AND SYSTEMS FOR GUIDE RNA DESIGN AND USE | Synthego Corporation (US) | 2021-03-24 | — | — | EP | claimed |
| WO-2020112979-A9 | THERAPEUTIC GENE EDITING FOR ELANE-ASSOCIATED DISEASE | BAUER DANIEL E (US) | 2020-07-23 | — | — | WO | claimed |
| WO-2020112979-A2 | THERAPEUTIC GENE EDITING FOR ELANE-ASSOCIATED DISEASE | BAUER DANIEL E (US) | 2020-06-04 | — | — | WO | claimed |
| US-20200095582-A1 | BCL11A GUIDE DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-03-26 | — | — | US | claimed |
| WO-2018218135-A1 | BCL11A GUIDE DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-11-29 | — | — | WO | claimed |
| WO-2018118587-A1 | MODIFIED POLYNUCLEOTIDES FOR ANTIVIRAL THERAPY | AGENOVIR CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| WO-2014152909-A1 | ALTERATION OF GENE EXPRESSION BY SYNTHETIC piRNAs AND BY ALTERATION OF piRNA FUNCTION | IBIS BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-8133669-B2 | Chemically modified nucleoside 5′-triphosphates for thermally initiated amplification of nucleic acid | TRILINK BIOTECHNOLOGIES (US) | 2012-03-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320496-A1 | MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | ABCB11, SLC10A1, SREBF1 | CYP3A4 2776/4885CYP1A2 2781/4885CYP2D6 3096/4885 |
| US-20250250575-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | CYP3A4 4372/4885CYP1A2 4226/4885CYP2D6 4299/4885 |
| US-20250243488-A1 | METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | GRN, SNRPE, UPF1 | CYP3A4 4875/4885CYP1A2 4840/4885CYP2D6 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.